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Blockade of the renin-angiotensin system
The renin-angiotensin-aldosterone system plays a key role in the regulation
of fluid and electrolyte balance. Angiotensin-converting enzyme inhibitors
inhibit angiotensin-converting enzyme and have been shown to be effective
in many cardiovascular diseases. They should be considered for the treat-
ment of hypertension in patients with heart failure, previous myocardial
infarction, diabetes, or proteinuria. There are a number of side-effects
associated with angiotensin-converting enzyme inhibitors, especially per-
sistent dry cough. Angiotensin II receptor antagonists (sartans) provide a
more specific blockade of the renin-angiotensin-aldosterone system and are
associated with fewer side-effects, including cough. Their long-term
efficacy and tolerability in the treatment of patients with hypertension has,
however, yet to be established. Periodic monitoring of renal function and
electrolytes is required in patients treated with an angiotensin-converting
enzyme inhibitor or a sartan.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) has a central role in regulat-
ing fluid and electrolyte balance (Fig). Renin is released in response to a
decrease in renal perfusion pressure, which can be due to hypotension. Renin is
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Fig. A simplified diagram illustrating the role of the renin-angiotensin-aldosterone
system in sodium and volume homeostasis
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an enzyme present in the plasma that cleaves angio-
tensinogen to form angiotensin I. Angiotensin I is relatively
inactive; its activity is increased 100-fold when it is
converted to angiotensin II by the angiotensin-converting
enzyme (ACE). Angiotensin II is a potent stimulant for the
contraction of vascular smooth muscle. It also stimulates
the synthesis and release of aldosterone from the adrenal
cortex. Aldosterone increases the absorption of sodium and
excretion of potassium in the distal tubules and collecting
ducts of nephrons in the kidney.
Angiotensin-converting enzyme inhibitors (ACEIs)
belong to a class of drugs which are increasingly used in the
management of a variety of diseases, including hypertension,
heart failure, myocardial infarction (MI), and diabetic and
other forms of nephropathy. Angiotensin-converting enzyme
inhibitors inhibit the formation of angiotensin II, which is a
powerful vasoconstrictor. They also indirectly reduce aldos-
terone secretion and so suppress the reabsorption of
sodium and excretion of potassium in the distal tubule.
Angiotensin-converting enzyme inhibitors have other effects
in addition to the ones on the RAAS. Indeed, ACE has been
described as a promiscuous enzyme. In addition to convert-
ing angiotensin I to angiotensin II, it has other substrates
such as kinins.1,2 Whereas angiotensin I is converted to the
more active angiotensin II by ACE, bradykinin is inacti-
vated by ACE. Angiotensin-converting enzyme inhibitors
inhibit ACE and may increase the level of bradykinin. More
studies are needed to determine whether the latter accounts
for part of the side-effects profile of ACEIs and whether or
not the potentiation of bradykinin is beneficial.
Angiotensin-converting enzyme inhibitor for the
treatment of hypertension
Angiotensin-converting enzyme inhibitors lower blood
pressure effectively and are one of the first-line drugs in the
treatment of hypertension.3,4 The latest results from the
STOP-hypertension-2 (Swedish Trial in Old Patients with
Hypertension-2) showed that there was no difference in terms
of all-cause mortality, cardiovascular mortality, and the risk
of a major cardiovascular event between an antihypertensive
regimen based on older drugs, ie diuretics and β-blockers,
and newer drugs, ie ACEIs and calcium channel blockers.5
This trial, along with the CAPP (CAptopril Prevention Project)
study,6 provide the scientific evidence for using ACEIs as
an alternative first-line treatment for hypertension.
Angiotensin-converting enzyme inhibitors may also have
additional beneficial effects. These include regression of left
ventricular hypertrophy (LVH) and remodelling of blood
vessels. In a meta-analysis of trials investigating agents
which regress LVH, ACEIs have been shown to be superior
to other classes of antihypertensive drugs.7 Left ventricular
hypertrophy is now recognised to be a potent risk factor
for cardiovascular events and mortality. Angiotensin-
converting enzyme inhibitors may also improve endothelial
dysfunction. The TREND (Trial on Reversing ENdothelial
Dysfunction) study showed that quinapril restores the
reactivity of vascular muscle to vasodilating agents in cor-
onary arteries.8 Angiotensin-converting enzyme inhibitors
may also reduce the thickness of arterial walls and restore
arterial compliance.9,10
If one chooses an ACEI for hypertension, one should
use a once-daily agent to minimise the peaks and troughs in
blood pressure and to improve compliance. Angiotensin-
converting enzyme inhibitors are not uniformly effective in
all individuals. The response to ACEI may have a genetic
component and may also be dependent on the degree of
activation of the RAAS.11,12 Younger hypertensive patients
may have a better blood pressure response to ACEIs than
elderly patients.13 If the blood pressure response to an ACEI
is unsatisfactory despite adequate dosage and compliance,
another class of antihypertensive drugs should be considered.
There are now a large number of ACEIs (Table 1). They
are largely similar in terms of their effects, but differ in some
Table 1. Angiotensin-converting enzyme inhibitors and sartans currently available in Hong Kong
Drug name Trade name Dosage Comments Major trials
Angiotensin-converting enzyme inhibitor
Captopril Capoten 12.5 mg bd*-50 mg td† Short-acting SAVE,22 ISIS-4,26 CAPP6
Cilazapril Inhibace 1 mg od‡-5 mg od - -
Enalapril Renitec 5-20 mg od - CONSENSUS,17,18
V-HeFT II,19 SOLVD20
Fosinopril Monopril 10-40 mg od Hepatic and renal route FACET32
of elimination
Lisinopril Zestril 2.5-20 mg od - GISSI-3,25 ATLAS21
Perindopril Acertil 2-8 mg od First-dose hypotension -
less likely
Quinapril Accupril 2.5-20 mg od-bd - QUIET27
Ramipril Tritace 1.25-10 mg od - AIRE,23 AIREX,24 HOPE28
Sartan
Candesartan Blopress 2-16 mg od - RESOLVD49
Irbesartan Aprovel 75-300 mg od - -
Losartan Cozaar 25-100 mg od - ELITE,47 ELITE II48
Valsartan Diovan 40-160 mg od - -
* bd twice a day
† td three times a day
‡ od once daily
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respects, particularly pharmacokinetics. Captopril was the
first ACEI developed and has a relatively short half-life,
necessitating two or three times a day dosages. Newer ACEIs
tend to have longer half-lives allowing once-daily dosage.
Some of the new ACEIs, such as fosinopril, are metab-
olised by the liver as well as excreted by the kidneys. This
dual route of excretion may be an advantage in patients who
have impaired renal function or in the elderly who may have
declining renal function but a normal plasma creatinine
level. Angiotensin-converting enzyme inhibitors also differ
in the extent of tissue binding. It is now known that in add-
ition to circulating angiotensin II, angiotensin II is also
present in tissue. The latter is generated by tissue ACE. It is
possible that the harmful effects of angiotensin II in tissue
may be reduced by treatment with ACEIs which achieve
higher tissue concentrations. Some ACEIs are claimed to
cause fewer side-effects. For example, first-dose hypoten-
sion is rare with perindopril while fosinopril is associated
with a lower incidence of cough.14,15 These claims are
interesting; however, their scientific basis has not been
elucidated.
As there are now numerous ACEIs to choose from, choice
will depend on prior experience of a particular drug,
availability, and price. Captopril has been used as a test
drug when ACEI therapy is started for the first time because
it is short-acting. For long-term use, a long-acting drug has
the theoretical advantage of once-daily dosage to achieve
improved compliance and smoother plasma levels. If
first-dose hypotension or renal impairment is a concern, then
perindopril or fosinopril, respectively, may be preferred.
When using some of the newer ACEIs, one is extrapolating
from clinical trials in which a different ACEI might have
been used, but the evidence so far suggests that the benefits
are class effects.
Concomitant medical conditions
Angiotensin-converting enzyme inhibitor therapy is
indicated in patients with hypertension who have
concomitant conditions such as heart failure, a history of
MI, or diabetes.
Heart failure
In heart failure, there is activation of the RAAS, resulting in
sodium and fluid retention. This may initially be a response
to low cardiac output but can be deleterious over time. It is
believed that such neurohormonal activation in heart failure
is harmful and should be counteracted with therapy.16
Angiotensin-converting enzyme inhibitors are effective in
suppressing the RAAS. Successive clinical trials such as
the CONSENSUS (COoperative North Scandinavian
ENalapril SUrvival Study),17,18 V-HeFT II (Vasodilator Heart
Failure Trial II),19 and SOLVD (Studies Of Left Ventricular
Dysfunction20) have shown that ACEIs reduce morbidity and
decrease hospitalisation due to heart failure (Table 2).
Furthermore, SOLVD showed that patients with a left
ventricular ejection fraction of 35% or less benefited from
treatment with an ACEI even if they were asymptomatic.
The initiation of treatment with ACEIs in patients with heart
failure should be closely monitored. The starting dose should
be low and increased gradually. Diuretics should be reduced
or stopped for a few days before introducing an ACEI so
as to avoid hypovolaemia, which exacerbates the effect of
first-dose hypotension. The optimal dose of an ACEI in heart
failure remains unresolved. In SOLVD, the target dose of
enalapril (20 mg daily) was quite high. In practice, most
physicians tend to use lower doses. The ATLAS (Assessment
of Treatment with Lisinopril And Survival) study showed
that high-dose ACEI therapy is more effective in reducing
cardiovascular events and preventing hospital admissions
compared with low-dose therapy.21 Ideally, one should there-
fore aim at using high doses.
Previous myocardial infarction
Large-scale studies such as the SAVE (Survival And
Ventricular Enlargement study),22 AIRE (Acute Infarction
Ramipril Efficacy study),23,24 GISSI (Gruppo Italiano per
lo Studio della Sopravvivenza nell’Infarcto miocardico),25
and the ISIS-4 (International Study of Infarct Survival26)
Table 2. Summary of the major clinical trials investigating the effect of treatment with angiotensin-converting enzyme inhibitors
or sartans on mortality
Trial Condition Drug Relative risk reduction (% deaths prevented)
CONSENSUS17,18 CHF* (NYHA† Class IV) Enalapril 40%
SOLVD20 CHF (EF‡ ≤35%) Enalapril 13%
SAVE22 MI§ (EF ≤40%) Captopril 19%
AIRE23 MI with HF❘❘ Ramipril 27%
AIREX24 MI with HF Ramipril 36%
GISSI-325 MI Lisinopril 11%
ISIS-426 MI Captopril 9%
HOPE28 CHD¶ Ramipril 16%
CAPP6 HT** Captopril Equivalent to treatment with a β-blocker
STOP-hypertension-25 HT Angiotensin-converting Equivalent to treatment with a diuretic/β-blocker; equiva-
enzyme inhibitor    lent to treatment with a calcium channel blocker
ELITE47 CHF Losartan Superior to treatment with captopril
ELITE II48 CHF Losartan Equivalent to treatment with captopril
RESOLVD49 CHF Candesartan Equivalent to treatment with enalapril
* CHF congestive heart failure ❘❘ HF heart failure
† NYHA New York Heart Association ¶ CHD coronary heart disease
‡ EF ejection fraction ** HT hypertension
§ MI myocardial infarction
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all testified to the efficacy of ACEIs in reducing long-term
mortality and improving cardiac function of patients after
MI (Table 2). By influencing cardiac remodelling follow-
ing MI, ACEIs help to prevent deterioration in ventricular
function and development of heart failure. Acute MI
patients with overt heart failure23 or poor ejection fractions22
appear to benefit most from these drugs, but all MI pa-
tients might benefit to some extent.25,26 Early initiation of
ACEIs in the first day after acute MI has been shown to
incur greater benefit.
Coronary heart disease
The survival benefit seen in patients with heart failure or
MI treated with ACEIs led to the hypothesis that ACEIs may
be beneficial for all patients at risk of dying from coronary
heart disease. The QUIET (QUinapril Ischemic Event Trial)
study was unable to show any significant coronary
angiographic improvements,27 but the HOPE (Heart
Outcomes Prevention Evaluation) study demonstrated an
across-the-board reduction in mortality regardless of
age-group, sex, previous MI, presence of hypertension,
heart failure, diabetes, or microalbuminuria.28 Angiotensin-
converting enzyme inhibitors therefore rank alongside
statins as useful therapy for primary and secondary preven-
tion of coronary heart disease.
Diabetes
The pioneering study by Lewis et al29 showed that captopril
prevented the progression of diabetic nephropathy. The
outcome measures were doubling of serum creatinine or
progression to dialysis or transplantation. Other studies
showed that ACEIs prevent the progression from micro-
albuminuria to albuminuria.30 Microalbuminuria (albumin
excretion 30-300 mg/24 hr) is an early marker for deteri-
oration in renal function, and is often present 10 years after
the onset of diabetes. Currently, it is thought that pa-
tients with diabetes with microalbuminuria or albuminuria
should receive an ACEI. For hypertensive patients with
diabetes, ACEI may well be the first choice treatment.
Diuretics and β-blockers, the first-line drugs in non-
diabetic, hypertensive patients, are viewed by some as
less suitable for treating hypertension in patients with
diabetes because of their metabolic effects. Calcium
channel blockers have been widely used in hypertensive
patients with diabetes, but recent data, especially from the
ABCD (Appropriate Blood pressure Control in Diabetes
trial) and FACET (Fosinopril versus Amlodipine Cardio-
vascular Events randomized Trial) studies, suggested that
such patients treated with an ACEI had fewer cardio-
vascular events than those treated with a calcium channel
blocker.31,32 The UKPDS 39 (UK Prospective Diabetes
Study 39),33 however, suggested that ACEIs and β-blockers
are equivalent in their effect on microvascular and macro-
vascular complications. It appears that tight control of blood
pressure in diabetics is as important, if not more so, as the
choice of drug.34 On the other hand, in CAPP and HOPE,
there was a lower incidence of diabetes in patients treated
with an ACEI.6,28
Adverse effects of angiotensin-converting enzyme
inhibitors
Since ACEIs inhibit the release of aldosterone, the sodium/
potassium exchange in the distal renal tubules is decreased
and potassium retention and hyperkalaemia may occur.
Hyperkalaemia is a common side-effect of ACEIs (Box) and
is especially likely in patients with poor baseline renal
function. Most physicians should be very cautious about
prescribing potassium supplements or potassium-sparing
diuretics, such as amiloride or spironolactone, in patients
treated concurrently with an ACEI.
When a person is volume or salt depleted, the RAAS is
activated. In these patients ACEIs may induce postural
hypotension, especially when it is the first dose. This
phenomenon has been termed ‘first-dose hypotension’ and
is a well-recognised side-effect. In patients at risk of first-
dose hypotension, such as those with severe heart failure
already receiving high-dose diuretics, those whose blood
pressure is already low, and elderly patients, ACEI therapy
should be initiated very carefully. In such patients, the dos-
age of diuretics should be reduced, at least temporarily, and
any hypovolaemia corrected. The lowest dose of an ACEI
should be used as the starting dose. The patient is advised
to remain recumbent for a few hours after the first dose.
Usually, this may mean taking the drug before going to bed.
In patients who require large doses of diuretics for the
treatment of heart failure, hospital admission may be
necessary for the initiation of ACEI therapy and the
titration of drugs. Perindopril is reported to have a lower
incidence of first-dose hypotension than other agents.14
In patients with renal impairment, ACEIs should be used
cautiously. Most ACEIs are excreted by the kidneys, thus
plasma drug levels will be higher in patients with pre-
existing renal disease. Moreover, ACEIs often reduce the
glomerular filtration rate and may markedly worsen
renal function, particularly in patients with bilateral renal
artery stenosis or stenosis in the renal artery of a single
Adverse effects associated with angiotensin-converting
enzyme inhibitor and sartan therapy
Adverse effects of angiotensin-converting enzyme inhibitor
Hypotension (especially following the first dose)
Persistent dry cough
Taste alteration
Renal impairment
Hyperkalaemia
Urticaria
Rashes
Angioedema
Hypersensitivity reactions
Blood disorders (anaemia, thrombocytopenia, neutropenia,
   agranulocytosis)
Jaundice
Adverse effects of sartan
Symptomatic hypotension
Hyperkalaemia
Rash
Angioedema
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functioning kidney. Some young patients with hypertension
have bilateral renal artery stenosis due to fibromuscular
hyperplasia. In the elderly, the renal arteries may be
narrowed by atherosclerosis. Hence, it is customary to be
cautious when prescribing an ACEI in patients with
peripheral vascular disease as they may have silent reno-
vascular disease. A sudden change in renal function after
the initiation of an ACEI in such patients should alert the
clinician to this possibility. The renal toxicity of ACEIs is
exacerbated when other nephrotoxic drugs are prescribed
concurrently. For example, non-steroidal anti-inflammatory
drugs should be prescribed with caution in a patient already
taking an ACEI. Angiotensin-converting enzyme inhibitors
tend to reduce the renal excretion of lithium and toxic plasma
levels of lithium may occur. Although ACEIs may reduce
glomerular filtration rate or cause dangerous hyperkalae-
mia in patients with renal failure, ACEIs are used in early
renal failure to retard disease progression.35 They have been
shown to slow down the deterioration of renal function in
diabetic and non-diabetic nephropathy.29,36,37 Angiotensin-
converting enzyme inhibition should be used with special
care in these patients, with their renal function closely
monitored.
None of the ACEIs have been tested in pregnant patients,
and this class of drugs should not be used in pregnancy.
Methyldopa (Aldomet), nifedipine, and in the third trimester,
β-blockers are drugs that can be used for the treatment of
hypertension during pregnancy.
Captopril used at high doses has been associated with
rare cases of thrombocytopenia, neutropenia, and
agranulocytosis. These effects are thought to be related to
the sulphhydryl group in captopril. Other ACEIs lacking the
sulphhydryl group have not been associated with these
problems. Angiotensin-converting enzyme inhibition may
depress erythropoiesis, which may pose a problem in pa-
tients with chronic renal failure. Occasionally ACEIs cause
hypersensitivity reactions, rash, urticaria, and angioneurotic
oedema. In such patients, use of ACEIs is contraindicated.
A common problem with ACEIs is that a proportion of
patients suffer from a persistent dry cough. This side-effect
may be caused by potentiation of kinins and substance P.
The cough tends to occur at night. It responds poorly to
cough mixtures and antihistamines, and may require a
reduction in dosage or withdrawal of the drug. The inci-
dence of dry cough is particularly high in Hong Kong
Chinese,38 and may be related to the high level of environ-
mental pollution.39 It is worth checking that the cough is
truly related to ACE inhibition. Sometimes, a careful
history may reveal that the cough is due to other reasons
such as common cold, chest infection, or worsening heart
failure. There is little evidence that cough mixtures
commonly prescribed are effective. If cough persists the in-
dications for an ACEI should be reviewed to see if another
class of drugs can be used instead. In those patients who
require an ACEI despite cough, it is worth trying inhaled
sodium cromoglycate, which is normally used for asthma.
There is some evidence from small trials that sodium
cromoglycate is effective and well tolerated.40 If there
are no budgetary restraints, an angiotensin II receptor
antagonist such as losartan, may be used instead of an
ACEI, as the former does not cause cough.
Sartans
The remarkable success of ACEIs in the treatment of
cardiovascular diseases has prompted the search for better
alternative drugs to block the renin-angiotensin system. The
ACE is a non-specific enzyme and blocking the ACE may
increase the levels of kinins. Moreover, the effectiveness of
ACE inhibition may reduce over time because of non-ACE
enzymatic pathways, eg chymases, and increased levels of
angiotensin I. Hence, angiotensin II receptor antagonists
(sartans) have been developed. This new class of antihyper-
tensive drugs has been launched in recent years.41 Unlike
the ACEIs, the sartans block the binding of angiotensin II to
one of its receptors (angiotensin II type 1 [AT1] receptors).
This G-protein-coupled AT1 receptor is believed to mediate
the physiological effects of angiotensin on the circulatory
system, such as vasoconstriction, aldosterone stimulation,
and sodium and water balance. Angiotensin II receptor
antagonists are expected to block the cardiovascular
effects of angiotensin II more completely, specifically, and
durably than ACEIs. The incidence of side-effects should
also be lower because of the specificity of the blockade. For
instance, angiotensin II receptor antagonists do not cause
cough which is commonly associated with ACEI therapy.42
The long-acting nature of the sartans also leads to a
lower incidence of first-dose hypotension. Evidence from
controlled clinical trials suggests that the sartans are very
well tolerated and generally have a side-effect profile
similar to placebo. The most frequently reported side-effect
is dizziness. This is not unexpected for a blood pressure–
lowering drug and is more likely to occur in patients who
are volume-depleted. Many of the cautions and contraindi-
cations to ACEIs also apply. For instance, the concurrent
use of potassium supplements and potassium-sparing
diuretics must be carefully judged. Plasma potassium and
creatinine should be measured before and after initiation
of therapy. As with ACEIs, sartans should not be used in
pregnancy or in women of reproductive age who may
become pregnant. Nor should sartans be used in patients
with bilateral renal artery stenosis and advanced renal
failure. There have also been rare incidents of angioedema
in patients treated with sartans. On the other hand, both
ACEIs and sartans can be safely given to hypertensive
patients with concomitant conditions such as diabetes,
hyperlipidaemia, gout, asthma, or heart failure.
Further knowledge of the pharmacology of angiotensin
II receptors has been gained from clinical use of sartans.
Sartans block the AT1 but not the AT2 receptor. At the same
time, angiotensin II levels increase. The unprotected stimu-
lation of AT2 receptors is of concern. Preliminary evidence
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suggests that stimulating the AT2 receptors enhances the
vasodilatory effects of sartans.43 The AT2 receptor is
expressed in human tissues but not to the same extent in rat
tissues, so extrapolating the effects of sartans in rat models
to man may be difficult or even misleading. The functions
of the AT2 receptor and the consequences of its long-term
stimulation require further clarification.
A large number of sartans are now approved for use
in the treatment of patients with hypertension, and this class
of antihypertensive drugs is endorsed in the WHO-ISH
Guidelines for the Management of Hypertension as one of
the first-line treatment agents.44 Nevertheless, there are
reasons why sartans should currently be used with reserva-
tion for the treatment of hypertension. Firstly, they are new
drugs and long-term studies investigating their effect on
the reduction of mortality in hypertension, such as the
LIFE (Losartan Intervention For Endpoint reduction in
hypertension study45) and the VALUE (Valsartan Anti-
hypertensive Long-term Use Evaluation trial46) studies
are not yet completed. Post-hoc analyses of the ELITE
(Evaluation of Losartan In The Elderly study) trial in heart
failure patients suggested a reduction in all-cause mortality
and sudden death in the losartan-treated group compared
with the captopril-treated one,47 but this was not confirmed
in the larger well-powered study, ELITE II.48 Indeed, the
captopril-treated group were found to have a lower all-cause
mortality (odds ratio=0.88; 95% confidence interval, 0.75-
1.05), although this did not reach statistical significance.
Another trial comparing a sartan with an ACEI in patients
with heart failure, RESOLVD (Randomized Evaluation of
Strategies for Left Ventricular Dysfunction), was terminated
prematurely because the results were negative.49 Secondly,
ACEIs block not only the RAAS but also enhance the for-
mation of kinins. There are animal data to suggest that some
of the beneficial effects of ACEI are brought about by
changes in the kinin system.2 Sartans have no direct effect
on the kinin system and, therefore, may not reproduce all
the benefits of ACEIs.50 Finally, the cost-effectiveness of
antihypertensive drugs vary enormously. The sartans are
all recently developed, patented drugs, and thus, are con-
siderably more expensive than diuretics and β-blockers. At
the present time, it cannot be said that they are superior in
terms of outcome, but they do appear to be superior in terms
of tolerability and incidence of side-effects.
Conclusions
Angiotensin-converting enzyme inhibitors have established
an enviable reputation, especially in the treatment of
heart failure and MI. There are many potential problems
and side-effects associated with ACEIs, and patients taking
ACEIs require periodic monitoring of renal function and
electrolytes. However, large clinical trials have established
the usefulness of ACEIs in hypertension, heart failure, MI,
and diabetic nephropathy, ensuring these agents an import-
ant place in the formulary. The role of sartans is less clear
at this time. Sartans lower blood pressure and are well
tolerated. However, they are more expensive than ACEIs.
Results of large clinical trials are needed before they can be
promoted widely as first-line treatment for hypertension.
For patients in whom ACEIs are indicated, but who are un-
able to tolerate side-effects such as cough, a sartan should
certainly be considered.
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